Communiqués Aditxt, Inc.

Actions

ADTX

US0070256047

Temps réel estimé Cboe BZX Autres places de cotation 16:28:10 01/07/2024			Varia. 5j.	Varia. 1 janv.
1,465 ^USD	+6,93%		+3,55%	-77,98%

12/06	Aditxt, Inc. annonce un défaut de paiement en raison du non remboursement du solde à la date d'échéance	CI
20/05	Aditxt, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Hello Alpha Partners with Evofem to Offer Phexxi as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare	28/06	AQ
Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare	27/06	PR
Aditxt : Accelaration/Increase of Financial Obligation Form 8 K	12/06	PU
Aditxt : Material Agreement - Form 8-K	28/05	PU
Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules	06/05	AQ
CORRECTING and REPLACING Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules	03/05	BU
Appili Therapeutics Signs Definitive Agreement to be acquired by Aditxt, Inc.	03/04	AQ
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense	03/04	AQ
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)	02/04	BU
Evofem Biosciences - For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy	08/03	AQ
For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy	07/03	PR
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023	01/02	PR
Aditxt, Inc. Acquires Proprietary Electroencephalography Brain Monitoring Technologies and Devices, Including NeuroCap and NeuroEEG for Telehealth and Tele-neurology Applications	31/01	AQ
Aditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap™ and NeuroEEG™ for Telehealth and Tele-neurology Applications	30/01	BU
Aditxt, Inc.'s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.'s Proprietary Mitomic Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million	09/01	AQ
Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules	08/01	AQ
Aditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million	08/01	BU
Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules	05/01	BU
Aditxt, Inc. Regains Compliance with Nasdaq Stockholders Equity Requirement	03/01	AQ
Aditxt, Inc. Regains Compliance with Nasdaq Stockholders’ Equity Requirement	02/01	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Aditxt, Inc.

Actions

ADTX

US0070256047

Communiqués

Filtres